- Trials with a EudraCT protocol (511)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
511 result(s) found for: Acute heart failure.
Displaying page 6 of 26.
EudraCT Number: 2019-000439-14 | Sponsor Protocol Number: CMBG453C12201 | Start Date*: 2021-03-17 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A phase II multi-center, single arm, safety and efficacy study of MBG453 in combination with azacitidine and venetoclax for the treatment of Acute Myeloid Leukemia (AML) in adult patients unfit for... | |||||||||||||
Medical condition: Acute Myeloid Leukemia (AML) in adult patients unfit for chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Prematurely Ended) FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002732-25 | Sponsor Protocol Number: 0105 | Start Date*: 2006-02-01 |
Sponsor Name:Geir Øystein Andersen, Department of Cardiology, Ulleval University Hospital | ||
Full Title: Safety and efficacy of levosimendan in patients with acute myocardial infarction complicated by symptomatic left ventricular failure | ||
Medical condition: Patients with acute myocardial infarction developing acute heart failure after primary PCI (percutaneus coronary intervention). Some patients in a predefined subgroup are categorized as patients in... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000664-31 | Sponsor Protocol Number: D169DC00001 | Start Date*: 2020-08-12 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Registry-based, Randomised, Double-blind, Placebo-Controlled Cardiovascular Outcomes Trial to Evaluate the Effect of Dapagliflozin on Cardiometabolic Outcomes in Patients without Diabetes with Ac... | ||
Medical condition: Acute Myocardial Infarction, Heart failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2007-003666-17 | Sponsor Protocol Number: CS/2007/2608 | Start Date*: 2007-11-09 | |||||||||||
Sponsor Name:University Hospitals Bristol NHS Foundation Trust | |||||||||||||
Full Title: The ATACAS Trial: Aspirin and Tranexamic Acid for Coronary Artery Surgery Trial | |||||||||||||
Medical condition: Ischamic heart disease operated | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005426-18 | Sponsor Protocol Number: DECONGEST_v1.0 | Start Date*: 2022-03-02 | |||||||||||
Sponsor Name:UZ Brussel | |||||||||||||
Full Title: Diuretic Treatment in Acute Heart Failure with Volume Overload Guided by Serial Spot Urine Sodium Assessment | |||||||||||||
Medical condition: Acute Heart Failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001508-13 | Sponsor Protocol Number: COL-CHIPHF-P24 | Start Date*: 2021-08-06 |
Sponsor Name:Johann Wolfgang Goethe-Universität Frankfurt | ||
Full Title: Randomized, controlled, double-blind trial to investigate the effect of colchicin on the endothelial function in patients with CHIP mutations and chronic heart failure with reduced left ventricular... | ||
Medical condition: Ischemic heart failure with reduced ejection fraction | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2010-023809-36 | Sponsor Protocol Number: GIMEMAAML1310 | Start Date*: 2011-10-26 | |||||||||||
Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO | |||||||||||||
Full Title: Risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. | |||||||||||||
Medical condition: Acute myeloid leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001323-12 | Sponsor Protocol Number: PEVOLAM | Start Date*: 2020-09-23 | |||||||||||
Sponsor Name:Fundación PETHEMA | |||||||||||||
Full Title: A randomized phase III, multicentre, open label clinical trial comparing azacitidine plus pevonedistat versus azacitidine in Older/Unfit patients with newly diagnosed acute myeloid leukemia who are... | |||||||||||||
Medical condition: Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003117-33 | Sponsor Protocol Number: Pevonedistat-2002 | Start Date*: Information not available in EudraCT | |||||||||||||||||||||
Sponsor Name:Millennium Pharmaceuticals, Inc. | |||||||||||||||||||||||
Full Title: A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unf... | |||||||||||||||||||||||
Medical condition: Acute Myeloid Leukemia (AML) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: PL (Trial now transitioned) IT (Trial now transitioned) FR (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002019-16 | Sponsor Protocol Number: U-2015-030 | Start Date*: 2016-09-06 | |||||||||||
Sponsor Name:Uppsala Clinical Research center | |||||||||||||
Full Title: Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction | |||||||||||||
Medical condition: Heart Failure with Preserved Ejection Fraction, HFPEF | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003910-38 | Sponsor Protocol Number: SY-1425-202 | Start Date*: 2021-11-04 | |||||||||||
Sponsor Name:Syros Pharmaceuticals, Inc. | |||||||||||||
Full Title: Tamibarotene in Combination with Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-positive AML Who Are Ineligible for Standard Induction Therapy | |||||||||||||
Medical condition: RARA-positive acute myeloid leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005461-14 | Sponsor Protocol Number: LD-VenEx | Start Date*: 2022-04-20 |
Sponsor Name:Righospitalet | ||
Full Title: The Nordic AML Group – LD-VenEx: PHASE II STUDY OF AZACITIDINE IN COMBINATION WITH LOW DOSE VENETOCLAX IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (INCLUDING EXPLORATORY EVALUATION OF EX VIVO DRUG SENS... | ||
Medical condition: Acute Myelogenic Leukemia is aggressiv leukemia and treatment i challenging specialy in patients not eligible for intensiv chemotherapy or relapsed after intensiv chemotherapy.In this study we will... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Trial now transitioned) DK (Trial now transitioned) FI (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004748-27 | Sponsor Protocol Number: EPIDAURUS-2020 | Start Date*: 2022-04-21 | |||||||||||
Sponsor Name:LMU University Hospital Munich | |||||||||||||
Full Title: Escalated single platelet inhibition for one month plus direct oral anticoagulation in patients with atrial fibrillation and acute coronary syndrome undergoing percutaneous coronary intervention | |||||||||||||
Medical condition: Patients with atrial fibrillation and ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) (biomarker -positive acute coronary syndrome) und... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003676-22 | Sponsor Protocol Number: TMC-CLV-08-01 | Start Date*: 2009-04-01 | ||||||||||||||||
Sponsor Name:The Medicines Company | ||||||||||||||||||
Full Title: A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure – A Pilot Study (PRONTO) | ||||||||||||||||||
Medical condition: acute heart failure and elevated BP (systolic blood pressure [SBP] ≥160 mm Hg) requiring parenteral IV antihypertensive therapy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-024249-59 | Sponsor Protocol Number: ULA01 | Start Date*: 2012-10-18 |
Sponsor Name:Cardiorentis Ltd. | ||
Full Title: Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ularitide (Urodilatin) Intravenous Infusion in Patients Suffering from Acute Decomp... | ||
Medical condition: Acute Decompensated Heart Failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) DE (Prematurely Ended) HU (Prematurely Ended) NL (Prematurely Ended) FI (Prematurely Ended) IT (Completed) LT (Prematurely Ended) EE (Prematurely Ended) LV (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) SE (Ongoing) BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-001183-31 | Sponsor Protocol Number: MT18328 | Start Date*: 2005-10-20 |
Sponsor Name:F. Hoffmann-La Roche Ltd | ||
Full Title: A prospective, open label, randomized, multicenter, multinational study evaluating the overall efficacy and safety including the effect on renal function of sirolimus (Rapamune) replacing CNI in a... | ||
Medical condition: Heart Transplant | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) AT (Completed) CZ (Completed) GB (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-000540-26 | Sponsor Protocol Number: CVT-CV-002 | Start Date*: 2013-05-12 | |||||||||||
Sponsor Name:CVie Therapeutics Company Limited | |||||||||||||
Full Title: The clinical study of the safety and efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure - A multicenter, randomized, double-blind, placebo controlled, parallel group clinical ... | |||||||||||||
Medical condition: Acute heart failure decompensated | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002168-17 | Sponsor Protocol Number: BAY94-8862/16275 | Start Date*: 2015-12-09 | |||||||||||||||||||||||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||||||||||||||||||||||
Full Title: A multicenter, randomized, double-blind, double-dummy, parallel-group, active-controlled study to evaluate the efficacy and safety of finerenone compared to eplerenone on morbidity and mortality in... | |||||||||||||||||||||||||||||||||
Medical condition: Subjects with chronic heart failure and reduced ejection fraction after recent heart failure decompensation and additional risk factors, either type 2 diabetes mellitus or chronic kidney disease or... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended) IE (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) FI (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) HU (Prematurely Ended) NL (Prematurely Ended) PT (Prematurely Ended) ES (Prematurely Ended) LT (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-014377-40 | Sponsor Protocol Number: Bay 58-2667/14560 | Start Date*: 2010-01-08 | |||||||||||
Sponsor Name:Bayer Healthcare AG | |||||||||||||
Full Title: A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenousl... | |||||||||||||
Medical condition: Acute Decompensated Chronic Congestive Heart Failure (ADHF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended) AT (Prematurely Ended) SK (Prematurely Ended) SI (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002882-20 | Sponsor Protocol Number: 2013-03 | Start Date*: 2013-12-18 |
Sponsor Name:Västra Götalands Center för utveckling av prehospital akutsjukvård | ||
Full Title: DETermination of the role of OXygen in Acute Myocardial Infarction (DETO₂X-AMI) trial | ||
Medical condition: Acute myocardial infarction | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
